Randomized controlled oncology trials with tumor stage inclusion criteria

Background:
Extracting inclusion and exclusion criteria in a structured, automated fashion remains a challenge to developing better search functionalities or automating systematic reviews of randomized controlled trials in oncology. The question “Did this trial enroll patients with localized disease, metastatic disease, or both?” could be used to narrow down the number of potentially relevant trials when conducting a search.
Dataset collection:
600 randomized controlled trials from high-impact medical journals were classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits.
Data properties:
Each trial is a row in the csv file. For each trial there is a doi, a publication date, a title, an abstract, the abstract sections (introduction, methods, results, conclus..., Randomized controlled oncology trials from seven major journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023 were randomly sampled and annotated with the labels “LOCAL”, “METASTATIC”, both or none. Trials that allowed for the inclusion of patients with localized disease received the label “LOCAL”. Trials that allowed for the inclusion of patients with metastatic disease received the label “METASTATIC”. Trials that allowed for the inclusion of patients with either localized or metastatic disease received bot labels. Screening trials that enrolled patients without known cancer or trials of interventions to prevent cancer were assigned no label. Trials of tumor entities where the distinction between localized and metastatic disease is usually not made (e.g., hematologic malignancies) were skipped. Annotation was based on the title and abstract. If those were inconclusiv..., , # Randomized controlled oncology trials with tumor stage inclusion criteria

[https://doi.org/10.5061/dryad.g4f4qrfzn](https://doi.org/10.5061/dryad.g4f4qrfzn)

600 randomized controlled oncology trials from high-impact medical journals (British Medical Journal, JAMA, JAMA Oncology, Journal of Clinical Oncology, Lancet, Lancet Oncology, New England Journal of Medicine) published between 2005 and 2023** **were randomly sampled and classified depending on whether they allowed for the inclusion of patients with localized and/or metastatic disease. The dataset was randomly split into a training/validation and a test set of 500 and 100 trials respectively. However, the sets could be merged to allow for different splits.

## Description of the data and file structure

Each trial is a row in the csv file. For each trial there are the follwing columns:

* doi: Digital Object Identifier of the trial
* date: Publication data according to PubMed
* title: Title of the trial according to PubMed
* ab...